The requirement of blood in India is estimated to be 8.5 million to 10 million units/per year, whereas the available supply is only 7.4 million units/per year
UNICEF award is worth US $98.755 million for supply of around 99.70 million doses during calendar years 2023-2027
The ANDA was filed as 'First to File' submission on NCE-1 date.
Tanner will be the supplier of olverembatinib to healthcare providers on a named patient basis in countries where the drug is not commercially available.
She joins Enveda from Gilead Sciences
An algorithm based testing for Fatty Liver Disease
Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
SCG101 is an autologous T-cell receptor (TCR) T-cell therapy for liver cancer
Subscribe To Our Newsletter & Stay Updated
